This clinical trial focuses on adults with Type 1 Diabetes, a condition where the body does not produce insulin naturally, requiring daily insulin injections to control blood sugar levels. The study will compare two different insulin treatments: a new once-weekly insulin called insulin icodec and a standard once-daily insulin glargine. Both treatments will be used in combination with insulin aspart, which is taken at mealtimes to control blood sugar.
The purpose of this research is to evaluate how well the weekly insulin icodec controls blood sugar levels compared to daily insulin glargine in people with Type 1 Diabetes. The study will use pre-filled injection pens called FlexTouch to deliver the insulin medications under the skin. Participants will receive either weekly insulin icodec or daily insulin glargine for 26 weeks.
During the study, blood sugar control will be monitored through various measurements, including HbA1c (a blood test that shows average blood sugar levels over the past few months) and continuous glucose monitoring using a device called Dexcom G7. The study will also track other important factors such as the number of low blood sugar episodes and changes in body weight.



Germany
Poland
Romania
Slovakia